17 research outputs found
Sex steroid priming for growth hormone stimulation testing in children and adolescents with short stature: AÂ systematic review
Type 1 diabetes incidence in Scotland between 2006 and 2019
Aims: To describe type 1 diabetes incidence in Scotland between 2006 and 2019. Methods: Repeated annual crossâsectional studies of type 1 diabetes incidence were conducted. Incident cases were identified from the Scottish Care InformationâDiabetes Collaboration (SCIâDC), a populationâbased register of people with diagnosed diabetes derived from primary and secondary care data. Midâyear population estimates for Scotland were used as the denominator to calculate annual incidence with stratification by age and sex. Joinpoint regression was used to investigate whether incidence changed during the study period. Age and sexâspecific type 1 diabetes incidence over the whole time period was estimated by quintile of the Scottish Index of Multiple Deprivation (SIMD), an areaâbased measure, in which Q1 and Q5 denote the most and least deprived fifths of the population, respectively, with quasiâPoisson regression used to compare incidence for Q5 compared to Q1. Results: The median (IQR) age of the study population of 14,564 individuals with incident type 1 diabetes was 24.1 (12.3â42.4) years, 56% were men, 23% were in Q1 and 16% were in Q5. Incidence of T1DM was higher in men than women overall (at around 22 and 17 per 100,000, respectively) and in under 15 year olds (approximately 40 per 100,000 in both sexes) than other age groups and was similar across the study period in all strata. There was an inverse association between socioâeconomic status and type 1 diabetes incidence for 15â29, 30â49 and 50+ year olds [incidence rate ratio (IRR) for Q5 compared to Q1; IRR (95% CI) 0.52 (0.47â0.58), 0.68 (0.61â0.76) and 0.53(0.46â0.61), respectively] but not for under 15 year olds [1.02 (0.92â1.12)]. Conclusion: Incidence of type 1 diabetes varies by age, sex and socioâeconomic status and has remained approximately stable from 2006 to 2019 in Scotland
The Long-term Outcomes of Sacral Neuromodulation for Fecal Incontinence: A Single Center Experience
Partial diazoxide responsiveness in a neonate with hyperinsulinism due to homozygous ABCC8 mutation
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulinaemic hypoglycaemia (CHI) due to a homozygous ABCC8 mutation. A term baby, with birth weight 3.8 kg, born to consanguineous parents presented on day 1 of life with hypoglycaemia. Hypoglycaemia screen confirmed CHI. Diazoxide was commenced on day 7 due to ongoing elevated glucose requirements (15 mg/kg/min), but despite escalation to a maximum dose (15 mg/kg/day), intravenous (i.v.) glucose requirement remained high (13 mg/kg/min). Genetic testing demonstrated a homozygous ABCC8 splicing mutation (c.2041-1G>C), consistent with a diffuse form of CHI. Diazoxide treatment was therefore stopped and subcutaneous (s.c.) octreotide infusion commenced. Despite this, s.c. glucagon and i.v. glucose were required to prevent hypoglycaemia. A trial of sirolimus and near-total pancreatectomy were considered, however due to the significant morbidity potentially associated with these, a further trial of diazoxide was commenced at 1.5 months of age. At a dose of 10 mg/kg/day of diazoxide and 40 ”g/kg/day of octreotide, both i.v. glucose and s.c. glucagon were stopped as normoglycaemia was achieved. CHI due to homozygous ABCC8 mutation poses management difficulties if the somatostatin analogue octreotide is insufficient to prevent hypoglycaemia. Diazoxide unresponsiveness is often thought to be a hallmark of recessively inherited ABCC8 mutations. This patient was initially thought to be non-responsive, but this case highlights that a further trial of diazoxide is warranted, where other available treatments are associated with significant risk of morbidity. Learning points: Homozygous ABCC8 mutations are commonly thought to cause diazoxide non-responsive hyperinsulinaemic hypoglycaemia. This case highlights that partial diazoxide responsiveness in homozygous ABCC8 mutations may be present. Trial of diazoxide treatment in combination with octreotide is warranted prior to considering alternative treatments, such as sirolimus or near-total pancreatectomy, which are associated with more significant side effects.This article is freely available via Open Access. Click on the Publisher's URL to access the full-text
A new multi-system disorder caused by the Gαs mutation p.F376V
Context
The alpha-subunit of the stimulatory G-protein (Gαs) links numerous receptors to adenylyl cyclase. Gαs, encoded by GNAS, is expressed predominantly from the maternal allele in certain tissues. Thus, maternal heterozygous loss-of-function mutations cause hormonal resistance, as in pseudohypoparathyroidism type Ia, while somatic gain-of-function mutations cause hormone-independent endocrine stimulation, as in McCune-Albright Syndrome.
Objective
We here report two unrelated boys presenting with a new combination of clinical findings that suggest both gain and loss of Gαs function.
Design, Setting
Clinical features were studied and sequencing of GNAS was performed. Signaling capacities of wild-type and mutant-Gαs were determined in the presence of different G protein-coupled receptors (GPCRs) under basal and agonist-stimulated conditions.
Results
Both unrelated patients presented with unexplained hyponatremia in infancy, followed by severe early-onset gonadotrophin-independent precocious puberty and skeletal abnormalities. An identical heterozygous de novo variant (c.1136T>G; p.F376V) was found on the maternal GNAS allele, in both patients; this resulted in a clinical phenotype that differ from known Gαs-related diseases and suggested gain-of-function at the receptors for vasopressin (V2R) and lutropin (LHCGR), yet increased serum parathyroid hormone (PTH) concentrations indicative of impaired proximal tubular PTH1 receptor (PTH1R) function. In vitro studies demonstrated that Gαs-F376V enhanced ligand-independent signaling at the PTH1R, LHCGR and V2R and, at the same time, blunted ligand-dependent responses. Structural homology modeling suggested mutation-induced modifications at the C-terminal α5-helix of Gαs that are relevant for interaction with GPCRs and signal transduction.
Conclusions
The Gαs p.F376V mutation causes a previously unrecognized multi-system disorder
Too Big to Fail â U.S. Banksâ Regulatory Alchemy: Converting an Obscure Agency Footnote into an âAt Willâ Nullification of Dodd-Frankâs Regulation of the Multi-Trillion Dollar Financial Swaps Market
The multi-trillion-dollar market for, what was at that time wholly unregulated, over-the-counter derivatives (âswapsâ) is widely viewed as a principal cause of the 2008 worldwide financial meltdown. The Dodd-Frank Act, signed into law on July 21, 2010, was expressly considered by Congress to be a remedy for this troublesome deregulatory problem. The legislation required the swaps market to comply with a host of business conduct and anti-competitive protections, including that the swaps market be fully transparent to U.S. financial regulators, collateralized, and capitalized. The statute also expressly provides that it would cover foreign subsidiaries of big U.S. financial institutions if their swaps trading could adversely impact the U.S. economy or represent the use of extraterritorial trades as an attempt to âevadeâ Dodd-Frank. In July 2013, the CFTC promulgated an 80-page, triple-columned, and single-spaced âguidanceâ implementing Dodd-Frankâs extraterritorial reach, i.e., that manner in which Dodd-Frank would apply to swaps transactions executed outside the United States. The key point of that guidance was that swaps trading within the âguaranteedâ foreign subsidiaries of U.S. bank holding company swaps dealers were subject to all of Dodd-Frankâs swaps regulations wherever in the world those subsidiariesâ swaps were executed. At that time, the standardized industry swaps agreement contemplated that, inter alia, U.S. bank holding company swaps dealersâ foreign subsidiaries would be âguaranteedâ by their corporate parent, as was true since 1992. In August 2013, without notifying the CFTC, the principal U.S. bank holding company swaps dealer trade association privately circulated to its members standard contractual language that would, for the first time, âdeguaranteeâ their foreign subsidiaries. By relying only on the obscure footnote 563 of the CFTC guidanceâs 662 footnotes, the trade association assured its swaps dealer members that the newly deguaranteed foreign subsidiaries could (if they so chose) no longer be subject to Dodd-Frank. As a result, it has been reported (and it also has been understood by many experts within the swaps industry) that a substantial portion of the U.S. swaps market has shifted from the large U.S. bank holding companies swaps dealers and their U.S. affiliates to their newly deguaranteed âforeignâ subsidiaries, with the attendant claim by these huge big U.S. bank swaps dealers that Dodd-Frank swaps regulation would not apply to these transactions. The CFTC also soon discovered that these huge U.S. bank holding company swaps dealers were âarranging, negotiating, and executingâ (âANEâ) these swaps in the United States with U.S. bank personnel and, only after execution in the U.S., were these swaps formally âassignedâ to the U.S. banksâ newly âdeguaranteedâ foreign subsidiaries with the accompanying claim that these swaps, even though executed in the U.S., were not covered by Dodd-Frank. In October 2016, the CFTC proposed a rule that would have closed the âdeguaranteeâ and âANEâ loopholes completely. However, because it usually takes at least a year to finalize a âproposedâ rule, this proposed rule closing the loopholes in question was not finalized prior to the inauguration of President Trump. All indications are that it will never be finalized during a Trump Administration. Thus, in the shadow of the recent tenth anniversary of the Lehman failure, there is an understanding among many market regulators and swaps trading experts that large portions of the swaps market have moved from U.S. bank holding company swaps dealers and their U.S. affiliates to their newly deguaranteed foreign affiliates where Dodd- Frank swaps regulation is not being followed. However, what has not moved abroad is the very real obligation of the lender of last resort to rescue these U.S. swaps dealer bank holding companies if they fail because of poorly regulated swaps in their deguaranteed foreign subsidiaries, i.e., the U.S. taxpayer. While relief is unlikely to be forthcoming from the Trump Administration or the Republican-controlled Senate, some other means will have to be found to avert another multi-trillion-dollar bank bailout and/or a financial calamity caused by poorly regulated swaps on the books of big U.S. banks. This paper notes that the relevant statutory framework affords state attorneys general and state financial regulators the right to bring so-called âparens patriaeâ actions in federal district court to enforce, inter alia, Dodd- Frank on behalf of a stateâs citizens. That kind of litigation to enforce the statuteâs extraterritorial provisions is now badly needed
Type 1 diabetes incidence in Scotland between 2006 and 2019
Aims: To describe type 1 diabetes incidence in Scotland between 2006 and 2019. Methods: Repeated annual crossâsectional studies of type 1 diabetes incidence were conducted. Incident cases were identified from the Scottish Care InformationâDiabetes Collaboration (SCIâDC), a populationâbased register of people with diagnosed diabetes derived from primary and secondary care data. Midâyear population estimates for Scotland were used as the denominator to calculate annual incidence with stratification by age and sex. Joinpoint regression was used to investigate whether incidence changed during the study period. Age and sexâspecific type 1 diabetes incidence over the whole time period was estimated by quintile of the Scottish Index of Multiple Deprivation (SIMD), an areaâbased measure, in which Q1 and Q5 denote the most and least deprived fifths of the population, respectively, with quasiâPoisson regression used to compare incidence for Q5 compared to Q1. Results: The median (IQR) age of the study population of 14,564 individuals with incident type 1 diabetes was 24.1 (12.3â42.4) years, 56% were men, 23% were in Q1 and 16% were in Q5. Incidence of T1DM was higher in men than women overall (at around 22 and 17 per 100,000, respectively) and in under 15 year olds (approximately 40 per 100,000 in both sexes) than other age groups and was similar across the study period in all strata. There was an inverse association between socioâeconomic status and type 1 diabetes incidence for 15â29, 30â49 and 50+ year olds [incidence rate ratio (IRR) for Q5 compared to Q1; IRR (95% CI) 0.52 (0.47â0.58), 0.68 (0.61â0.76) and 0.53(0.46â0.61), respectively] but not for under 15 year olds [1.02 (0.92â1.12)]. Conclusion: Incidence of type 1 diabetes varies by age, sex and socioâeconomic status and has remained approximately stable from 2006 to 2019 in Scotland
Singlet oxygen and natural substrates: functional polyunsaturated models for the photooxidative degradation of carotenoids
The primary chemical reactions of singlet molecular oxygen with polyunsaturated carotenoids are the focus of this research report. Model compounds that exhibit electronic properties and substituent pattern similar to natural carotenes, xanthophylls or apocarotenoids, respectively, were investigated with regard to photooxygenation reactivity. For dienes and trienes as substrates, high tandem reactivity was observed and hydroperoxy-endoperoxides were isolated as the secondary products of singlet oxygen reaction. The electronic gem-effect on the regioselectivity of the ene reaction is conserved also in vinylogous positions and thus appears to originate from a radical-stabilizing effect. In an attempt to combine different peroxide groups derived from natural products as a tool for new pharmaceutically active products, a dyade synthesis of an artemisinine-safranol with subsequent singlet oxygen addition was realized